Hi-Tech Pharmacal posts loss as prices decline

Hi-Tech Pharmacal, an Amityville-based maker of generic drugs, Hi-Tech Pharmacal, an Amityville-based maker of generic drugs, reported a loss of $4.6 million for its fourth quarter compared with a profit of nearly $10 million in the same period a year ago. The company's fiscal year ended April 30. (Sept. 10, 2012) Photo Credit: Steve Pfost

advertisement | advertise on newsday

Hi-Tech Pharmacal Co. lost money in the February-April period because of lower prices for its popular nasal spray and having to set aside money for potential legal settlements.

The Amityville-based drugmaker Tuesday reported a loss of $4.6 million for its fourth quarter compared with a profit of nearly $10 million for the period a year ago. The company's fiscal year ended April 30.

Sales for the fourth quarter fell 5 percent, year over year, to $58.5 million.

Despite this performance, which was below stock analysts' estimates, Hi-Tech shares Tuesday closed up $1.72, or 5 percent, to $35.25 in Nasdaq trading. Some investors were buoyed by the company's pledge to use some of its more than $100 million in cash to purchase new products.

"We're looking to acquire things," chief executive David Seltzer told analysts in a conference call. "We just want to make sure that they fit strategically and that we don't overpay."

Fluticasone nasal spray -- a generic version of the prescription Flonase used for allergies and sinus infections -- has been the company's primary sales driver. However, competition from another generic drugmaker has pushed prices down.

Hi-Tech would've been in the black if not for the creation of two reserve funds, totaling $16 million, to cover potential expenses from a pricing probe by Texas officials and a class-action lawsuit involving ads for allergy reliever Nasal Ease.

advertisement | advertise on newsday

For the full year, the drugmaker reported profits of $16 million compared with $48 million in fiscal 2012. Sales climbed 1 percent to $232 million.

Seltzer promised to roll out at least five generic drugs this year, including another nasal spray. He also predicted a new portfolio of brand-name drugs would boost the bottom line.

"The increase in research and development spending in our generic division enabled us to build a pipeline of products developed in house and some recently licensed products, which will drive our future growth," he added.

The company is in the midst of a $50-million expansion project in Suffolk County that will add about 110 people to its local workforce of 290; most have already been hired.

Fortune magazine has named Hi-Tech one of the fastest-growing U.S. public companies for two consecutive years.

The latest LI business news in your inbox daily. Get the Biz Briefing newsletter!

Comments

Newsday.com now uses Facebook for our comment boards. Please read our guidelines and connect your Facebook account to comment.

You also may be interested in: